PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.11
3rd Edition – July 2017
www.msfaccess.org
HIV drug resistance , Users Manual
December 2017
Guidelines
June 2017
HIV strategic information for impact
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
The way Forward
Executive Summary